
A critical flaw in the code behind most websites and a breach at one of the nation's largest lab companies landed in the same week. Here's what physicians should check, ask and tell patients now.
Cardiovascular events were fewer in patients with type 2 diabetes randomized to 2 years of the DPP-4 inhibitor linagliptin compared with glimepiride as add-on therapy to metformin, according to data from a phase III study.




